Trouble Viewing This Email: Click Here

September 19, 2023


5 Excellent Finalists Chosen for the 8th Annual BHCR Crab Trap

Rockville, Maryland – September 13, 2023 – BioHealth Innovation, Inc. (BHI), a leading regional innovation intermediary, is thrilled to announce the five outstanding finalists for the 8th Annual BioHealth Capital Region Crab Trap competition. The Crab Trap is a competition designed to identify and showcase promising life sciences and biotechnology startups from around the world. These finalists have demonstrated exceptional innovation, vision, and potential to significantly impact the healthcare industry.

Read More

Last Chance to Register for the BioHealth Capital Region Forum 2023!

We're just ONE DAY away from the FREE 9th Annual BioHealth Capital Region Forum, and there's still time to register! Don't miss out on this incredible opportunity to join nearly 500 other registrants on September 19th and 20th. ๐Ÿ—“๏ธ

๐Ÿ“ Location: US Pharmacopeia (USP), 12601 Twinbrook Pkwy, Rockville, MD 20850
๐Ÿ‘” Attire: Business/Business Casual
๐Ÿš— Parking: Paid-parking garage across the street or metered-street parking
๐Ÿš‡ Metro: Twinbrook Metro stop on the Red Line (8-minute walk)

๐Ÿ”ฌ Why Attend?

  • Network with esteemed government officials, academic leaders, and industry executives.
  • Explore new avenues for growth within the BioHealth Capital Region.
  • Engage in thought-provoking discussions and knowledge sharing.
  • Discover investment and partnership opportunities in the vibrant biohealth industry.

๐Ÿ“ˆ The BioHealth Capital Region is a thriving hub of innovation and opportunity, boasting over 2,300 life science companies, 78 federal labs, and renowned academic institutions.

๐Ÿ‘‰ Register now to be a part of this prestigious event and help shape the future of the BioHealth Capital Region!

Visit to register now. 

Read More

Federal Trade Commission allows Amgen’s $27.8 billion acquisition of Horizon Therapeutics

THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon.

As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern District of Illinois, and that Amgen and Horizon will quickly seek the final approvals required under Irish law to close the acquisition.

Read More

Accelerate Investor Conference Returns to Showcase Leading Early-Stage Companies to National Investors

ARLINGTON, Va.--()--The Accelerate Investor Conference is back for its third year at George Mason University’s Arlington Campus, November 1-2, 2023. Spurring the region’s innovation and entrepreneurship engagement to a new level, the conference will showcase the Virginia, Maryland, and metropolitan DC region as a destination for business development, venture investment, and job creation.

Top venture firms from across North America participate to attend top keynotes and industry panels and watch 40+ high growth tech and life science companies pitch for their next round of capital. These cutting-edge startups compete for top prizes and are joined by 25 regional student teams presenting business concepts.

Read More

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

BETHESDA, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company has received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical study of its lead drug candidate GT-02287 in development for GBA1-Parkinson’s disease (GBA1-PD). Dosing in healthy volunteers to assess the safety and pharmacokinetics of GT-02287 is expected to begin in the near term.

Read More

Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).

Read More

PQE Group Opens Office in Montreal, Quebec, Canada

PQE Group is excited to announce the opening of its newest office in Montreal, Quebec, Canada, marking a significant expansion for the company. The expansion aims to provide enhanced services to both existing and potential clients across various regions in Canada. The Greater Montreal area, located along North America's east coast, is renowned for its vibrant life sciences community, featuring prestigious universities, leading hospitals, and innovative life sciences companies. Notably, Quebec serves as a hub for the development and acceleration of artificial intelligence (AI), reflecting its forward-thinking approach to shaping the future. Canada's expertise in AI, characterized by its high-quality research, skilled workforce, and contributions to AI innovation on a global scale, has been a key source of inspiration for PQE Group.

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright  BioHealth Innovation 2023
All Rights Reserved.